Stockscreener 앱 받기
116.23
1.93%
2.205
시간 외 거래:
118.90
2.67
+2.30%
전일 마감가:
$114.03
열려 있는:
$114.38
하루 거래량:
930.57K
Relative Volume:
0.73
시가총액:
$12.56B
수익:
$769.10M
순이익/손실:
$46.67M
주가수익비율:
332.09
EPS:
0.35
순현금흐름:
$119.79M
1주 성능:
+0.11%
1개월 성능:
+5.25%
6개월 성능:
+173.55%
1년 성능:
+35.97%
1일 변동 폭
$113.90
$117.31
1주일 범위
$111.94
$120.51
52주 변동 폭
$28.66
$126.38
코르셉트 테라퓨틱스 Stock (CORT) Company Profile
명칭
Corcept Therapeutics Inc
전화
650.688.8803
주소
101 REDWOOD SHORES PARKWAY, REDWOOD CITY
Compare CORT vs VRTX, MRNA, REGN, ARGX, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CORT
Corcept Therapeutics Inc
|
116.23 | 12.55B | 769.10M | 46.67M | 119.79M | 0.35 |
VRTX
Vertex Pharmaceuticals Inc
|
504.73 | 127.93B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
190.01 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
735.20 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.21 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
206.64 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
코르셉트 테라퓨틱스 Stock (CORT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-05-13 | 업그레이드 | UBS | Neutral → Buy |
| 2026-03-26 | 업그레이드 | Wolfe Research | Underperform → Peer Perform |
| 2025-12-31 | 다운그레이드 | Wolfe Research | Peer Perform → Underperform |
| 2025-12-16 | 개시 | UBS | Neutral |
| 2025-11-18 | 개시 | Wolfe Research | Peer Perform |
| 2023-11-06 | 업그레이드 | Truist | Hold → Buy |
| 2023-04-11 | 개시 | SVB Securities | Market Perform |
| 2023-04-04 | 개시 | Piper Sandler | Overweight |
| 2023-02-15 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-08-01 | 다운그레이드 | Truist | Buy → Hold |
| 2022-07-27 | 업그레이드 | Jefferies | Hold → Buy |
| 2022-06-27 | 재개 | Canaccord Genuity | Buy |
| 2022-02-02 | 개시 | Canaccord Genuity | Buy |
| 2022-01-28 | 개시 | Truist | Buy |
| 2020-08-05 | 다운그레이드 | Jefferies | Buy → Hold |
| 2019-09-24 | 개시 | Jefferies | Buy |
| 2019-09-06 | 개시 | H.C. Wainwright | Buy |
| 2019-02-04 | 다운그레이드 | B. Riley FBR | Buy → Neutral |
| 2018-08-10 | 재확인 | Stifel | Hold |
| 2018-05-31 | 다운그레이드 | Stifel | Buy → Hold |
| 2018-03-09 | 개시 | B. Riley FBR, Inc. | Buy |
| 2017-08-31 | 개시 | Stifel | Buy |
| 2017-02-02 | 개시 | Ladenburg Thalmann | Buy |
| 2015-04-21 | 개시 | FBR Capital | Outperform |
| 2014-01-13 | 다운그레이드 | Stifel | Buy → Hold |
| 2013-08-09 | 다운그레이드 | Janney | Buy → Neutral |
| 2013-08-09 | 다운그레이드 | Ladenburg Thalmann | Buy → Neutral |
| 2012-02-21 | 재확인 | JMP Securities | Mkt Outperform |
| 2010-01-06 | 업그레이드 | Ladenburg Thalmann | Neutral → Buy |
| 2008-07-17 | 개시 | Rodman & Renshaw | Mkt Outperform |
| 2007-06-21 | 업그레이드 | Punk, Ziegel & Co | Mkt Perform → Accumulate |
모두보기
코르셉트 테라퓨틱스 주식(CORT)의 최신 뉴스
After a $1.13M September sale, Corcept (CORT) officer proposes another share sale. - Stock Titan
Non-controlling/minority interest of Corcept Therapeutics Incorporated. – HAN:HTD - TradingView
Corcept Therapeutics (CORT) business chief gifts shares; two custodial accounts acquire 5,000 each - Stock Titan
Corcept Therapeutics’ oncology president sells $29,842 in stock - Investing.com
Form 4 Corcept Therapeutics Incorporated For: 28 September By Investing.com - Investing.com Canada
Strong Commercial Execution and Pipeline Opportunities Propel Corcept Therapeutics (CORT) - Yahoo Finance
Corcept Therapeutics Announces New Endocrinology Division President - The Globe and Mail
The Escalator: Bavarian Nordic, Acumetis, Corcept and more - Medical Marketing and Media
Corcept Therapeutics (CORT) Short Interest & Short Float | Updated Sep 2026 $CORT - MarketBeat
About Corcept Therapeutics Incorporated rStock - Coinbase
CORT Looks 59.9% Overvalued on GF Value™ - gurufocus.com
Corcept Names Justin Gunn President of Endocrinology as Sean Maduck Retires - citybiz
Corcept Therapeutics' Sean Maduck to Resign as President of Corcept Endocrinology, to Serve as Consultant - TradingView
Corcept names Justin Gunn to lead endocrinology division By Investing.com - Investing.com Canada
Corcept Therapeutics: Justin Gunn to Succeed Maduck, Assume New Responsibilities Starting Oct 1 >CORT - Moomoo
Corcept Announces Planned Leadership Transition - Business Wire
CORT Stock Hits Highest Levels In 2026 – Cushing’s Syndrome Drug NDA Resubmission Extends 5-Session Rally - Stocktwits
Corcept Therapeutics (CORT) CHMP Backing Keeps Undervalued Narrative In Focus - Yahoo Finance
Corcept’s (CORT) Cancer Drug Just Cleared Europe’s Toughest Hurdle - Yahoo Finance
CHMP Backs CORT's Lifyorli Combo in Platinum-Resistant Ovarian Cancer - Your Wyoming Link
Corcept Therapeutics Incorporated(NasdaqCM: CORT) added to S&P 400 Health Care - marketscreener.com
Corcept Therapeutics Incorporated(NasdaqCM: CORT) dropped from S&P 600 - marketscreener.com
Corcept Therapeutics Incorporated(NasdaqCM: CORT) dropped from S&P 600 Health Care - marketscreener.com
Corcept Therapeutics shares surge 22% after Q2 beat, guidance raise - scanx.trade
Analysts Are Bullish on Top Healthcare Stocks: Corcept Therapeutics (CORT), Xenon (XENE) - The Globe and Mail
Corcept Therapeutics president Vieira sells $29,842 of stock By Investing.com - Investing.com South Africa
Corcept Therapeutics president Vieira sells $29,842 of stock - Investing.com
Corcept Therapeutics (CORT) oncology president sells shares under 10b5-1 plan - Stock Titan
Corcept Therapeutics Inc (CORT) Stock Price, Quote, News & History - Benzinga
Here’s How Much You Would Have Made Owning Corcept Therapeutics Stock In The Last 10 Years - webull.com
Merck, Astra, Roche and Corcept among winners of EU drug recommendations this week - Seeking Alpha
Corcept Therapeutics Incorporated Receives CHMP Recommendation For EU Marketing Authorization For Lifyorli (Relacorilant) Combined With Nab-Paclitaxel For Platinum-Resistant Ovarian Cancer - marketscreener.com
CORT Looks 57.2% Overvalued on GF Value™ Amid EMA Relacorilant N - gurufocus.com
Corcept Says EU Panel Backs Ovarian Cancer Drug Combination for Approval - marketscreener.com
Corcept’s relacorilant receives EU panel backing for ovarian cancer By Investing.com - Investing.com Canada
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant) - STT Info
Corcept Therapeutics (NASDAQ:CORT) Combines Strong Growth With a Constructive Technical Setup - ChartMill
Corcept (CORT) director offloads 10,000 shares under preset plan - Stock Titan
Will Korlym Continue to Aid CORT's Growth Through the Rest of 2026? - Eastern Progress
Corcept Grows to Mid-Cap on Institutional Support - FXEmpire
Form 144 | Corcept Therapeutics(CORT.US) Director Proposes to Sell 3.34 Million in Common Stocks - Moomoo
Corcept Therapeutics (CORT) director plans $3.34M stock sale - Stock Titan
Stock option exercise to drive 10,000-share sale at Corcept (NASDAQ: CORT) - Stock Titan
Corcept Therapeutics posts strong Q2 revenue, e... - Pluang
Corcept president Sean Maduck sells $2.86m in stock By Investing.com - Investing.com South Africa
Corcept Therapeutics Insider Sold Shares Worth $2,860,737, According to a Recent SEC Filing - marketscreener.com
Corcept Therapeutics Insider Sold Shares Worth $6,460,766, According to a Recent SEC Filing - marketscreener.com
Corcept president Sean Maduck sells $2.86m in stock - Investing.com
Corcept Therapeutics oncology president sells $6.46m in shares By Investing.com - Investing.com Australia
Corcept Therapeutics oncology president sells $6.46m in shares - investing.com
Corcept Therapeutics (CORT) CFO adds shares via plan and restricted awards - Stock Titan
코르셉트 테라퓨틱스 (CORT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
코르셉트 테라퓨틱스 주식 (CORT) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Vieira Roberto Wandenkolk | President, Oncology |
Sep 16 '26 |
Sale |
100.82 |
296 |
29,843 |
3,946 |
| Robb Gary Charles | Chief Business Officer |
Sep 17 '26 |
Option Exercise |
8.27 |
17,493 |
144,667 |
31,156 |
| Lyon Joseph Douglas | See Remarks |
Sep 14 '26 |
Option Exercise |
12.99 |
10,000 |
129,863 |
15,683 |
| Lyon Joseph Douglas | See Remarks |
Sep 14 '26 |
Sale |
113.49 |
10,000 |
1,134,947 |
5,683 |
| WILSON JAMES N | Director |
Sep 15 '26 |
Sale |
110.69 |
10,000 |
1,106,940 |
1,064,543 |
0.05%
0.82%
자본화:
|
볼륨(24시간):